Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zactima – Tyrosine Kinase Inhibitor

Drug (Brand / Generic)

Zactima / vandetanib / ZD6474)

Company / Licensee

AstraZeneca

Therapy Class

TKI

Product Description

Dual-acting TKI that targets VEGF receptor-2 (KDR) and EGFR

Current Indication

Medullary thyroid cancer

Market Sector

Oncology

Development Status

Approved in US
Expand
Close
Close
Close

Go Top